What one share of Immuneering holds
We are a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. We are developing and seeking to commercialize an entirely new category of anti-cancer medicines, Deep Cyclic Inhibitors, which we believe have the potential to be more effective and better tolerated targeted therapies.
Immuneering’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.98 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.98 |
| Cash and investments | $0.64 |
| Book value | $2.95 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.47 | −$3.44 | $0.01 | −$2.96 | — | −$4.54 |
| 2021 | $0.15 | −$2.46 | $0.00 | −$2.27 | — | $11.46 |
| 2022 | $0.01 | −$1.91 | $0.03 | −$1.70 | — | $4.16 |
| 2023 | $0.00 | −$1.88 | $0.01 | −$1.74 | — | $3.19 |
| 2024 | — | −$2.04 | $0.00 | −$1.84 | — | $1.38 |
| 2025 | — | −$1.27 | $0.00 | −$1.03 | — | $4.96 |
Common questions about Immuneering
How much does one share of Immuneering earn?
Over the last 12 months, Immuneering lost $0.98 for each share.
Does Immuneering pay a dividend?
Immuneering didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Immuneering’s book value per share?
Immuneering’s book value is $2.95 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Immuneering have?
Each share of Immuneering has $0.64 of cash and investments, as of June 30, 2026.
What is Immuneering’s free cash flow per share?
−$0.98 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Immuneering bought back shares?
Immuneering’s share count rose about 789% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.